Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Baxter Sheds Poorly Performing Blood Products Line For $540 Mil.

This article was originally published in The Gray Sheet

Executive Summary

Baxter will sell its blood collection and processing business to a pair of investment firms for $540 mil., it announced Oct. 3

You may also be interested in...

People In Brief

Northrup leaves Enzi: With Democrats poised to take the lead of the Senate Health, Education, Labor & Pensions (HELP) Committee, outgoing Chairman Michael Enzi's (R-Wyo.) health policy director Stephen Northrup, former executive director of the Medical Device Manufacturers Association, moves to the law firm Arent Fox Dec. 13 as senior government relations director. David Bowen, health policy director to Sen. Edward Kennedy (D-Mass.), likely will take over as majority director of health policy for the HELP committee in January, when Kennedy is expected to become chairman. The HELP committee has primary jurisdiction in the Senate over FDA activities...

QUOTED. 26 February 2020. Mark Leahey.

In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts